Lupin, drug major is planning to acquire companies and brands globally, including companies in US, Japan and China, in order to increase its global footprint. It is taking a three-pronged approach in its acquisition strategy, which also includes the domestic market. With this initiative, the Mumbai-based firm aims to take over companies which can provide it new technology and market access.
Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
